Healthcare stocks were leaning lower premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) marginally declining.
Astrazeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to certain patients, Bloomberg reported, citing people familiar with the negotiations. Shares of Astrazeneca were down more than 1% pre-bell.